Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-17T14:44:07.334Z Has data issue: false hasContentIssue false
  • English
  • Français

Brief Review: Rivastigmine, A Second Cholinesterase Inhibitor

Published online by Cambridge University Press:  02 December 2014

C. Patterson  and
D.B. Hogan
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Brief Report
Information
Canadian Journal of Neurological Sciences , Volume 28 , Supplement S1: Canadian Consensus Conference on Dementia , May 2001 , pp. S122 - S123
Copyright
Copyright © The Canadian Journal of Neurological 2001

References

1. Jann, MW. Rivastigmine, a new-generation Cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy 2000; 20(1): 1–12.Google Scholar
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV) Washington, DC. American Psychiatric Association, 1994.Google Scholar
3. McKhann, G, Drachman, D, Folstein, M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDAwork group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–944.Google Scholar
4. Folstein, MG, Folstein, SE, McHugh, PR. ‘Mini-Mental State’: a practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 1975; 12:189–198 CrossRefGoogle Scholar
5. Corey-Bloom, J, Anand, R, Veach, J. A randomized trial evaluating the efficacy and safety of ENA713 (rivastigmine tartrate), a new acetylecholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998; 1: 55–65.Google Scholar
6. Rosen, WG, Mohs, RC, Davis, KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–1364.Google Scholar
7. Reisberg, B, Schneider, L, Doody, R, et al. Clinical global measure of dementia: position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alz Dis Assoc Disord 1997; 11(Suppl 3): 8–18.Google Scholar
8. Rosler, M, Anand, R, Cicin-Sain, A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br Med J 1999; 318(7184): 633–638.Google Scholar
9. De Jong, R, Osterlund, OW, Roy, GW. Measurement of quality of life changes in patients with Alzheimer’s disease. Clin Ther 1989; 11: 545–554.Google ScholarPubMed
10. Reisberg, B, Ferris, SH, Deleon, MJ, Crook, T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136–1139.Google Scholar
11. Birks, J, Grimley Evans, J, Iakovidou, V,Tsolaki, M. Rivastigmine for Alzheimer’s disease (Cochrane Review). Cochrane Database Syst Rev 2000; 4: CD 001191.CrossRefGoogle Scholar
12. McKeith, IG, Perry, EK, Perry, RH. Diagnosis and treatment of dementia with Lewy bodies (DLB). Report of the Second Dementia with Levy Bodies International Workshop. Neurology 1999; 53: 902–905.CrossRefGoogle Scholar
13. McKeith, I, Del Ser, T, Pierfranco, S, et al. Efficacy of rivastigmine in dementia with Levy bodies: a randomised, double blind, placebo-controlled international study. Lancet 2000; 356: 2031–2036.Google Scholar
14. Cummings, JL, Mega, M, Gray, K, et al. The Neuropsychiatric Inventory: Comprehensive Assessment of Psychopatholgy in Dementia. Neurology 1994; 44: 2308–2314.Google Scholar